Cyclophosphamide therapy for scleroderma

Current Opinion in Rheumatology

Volumn 10, Issue 6, 1998, Pages 579-583

  Åkesson, Anita ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

CANCER; CAUSE OF DEATH; FIBROSING ALVEOLITIS; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA;

ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; SCLERODERMA, SYSTEMIC;

EID: 0031789970     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199811000-00012     Document Type: Review

References (17)

1. Dau PC, Kahaleh MB, Sagebiel RW: Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 1981, 24:1128-1136.
2. Åkesson A, Wollheim FA, Thysell H, Gustafson T, Forsberg L, Pahlm O, Wollmer P, Åkesson B: Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic slcerosis. Scand J Rheumatol 1988, 17:313-323.
3. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:743-751. Bronchoalveolar lavage was performed on patients with systemic sclerosis with and without alveolitis and on normal control subjects. Significant differences were found between groups in the BAL fluid of tumor necrosis factor α, interleukin-8, macrophage inflammatory protein 1α, and RANTES (regulated upon activation, normal T cell expressed and secreted).
4. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum tumor necrosis factor-α levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997, 24:663-665. Serum tumor necrosis factor α levels were examined by enzyme-linked immunosorbent assay in patients with limited SSc and diffuse SSc and in control subjects. Elevated levels were found in patients with limited SSc and diffuse SSc and correlated wtih the presence of pulmonary fibrosis and with the decreased vital capacity of the patients.
5. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993, 20:838-844.
6. Åkesson A, Scheja A, Lundin A, Wollheim FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994, 37:729-735.
7. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr: Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1290-1296.
8. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, König G, Fruhmann G: Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996, 154:400-406.
9. White B, Moore F, Wigley F, Wise R: Followup studies on pulmonary function in systemic sclerosis (SSc) patients with alveolitis treated with cyclophosphamide (CTX), compared to untreated patients with alveolitis, patients without alveolitis, and controls. Arthritis Rheum 1997, 40(suppl) 555.
10. Battle RW, Dawitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA, Tischler MD: Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996, 110:1515-1519.
11. Groen H, Bootsma H, Postma DS, Kallenberg CGM: Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 1993, 20:1055-1057.
12. Dahl M, Chalmers A, Wade J, Calverley D, Munt B: Ten year survival of a patient with advanced pulmonary hypertension and mixed connected tissue disease treated with immunosuppressive therapy. J Rheumatol 1992, 19:1807-1809.
13. Friedman DM, Mitnick HJ, Danilowicz D: Recovery from pulmonary hypertension in an adolescent with mixed connected tissue disease. Ann Rheum Dis 1992, 51:1001-1004.
14. Morelli S, Barbieri C, Sgreccia A, Ferrante L, Pittoni V, Conti F, Gualdi G, Polettini E, Carlesimo OA, Calvieri S: Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997, 24:81-85. Twenty-eight patients with diffuse and 24 patients with limited SSc underwent pulmonary function studies, high-resolution CT of the lungs, and Doppler echocardiography. Extent and severity of cutaneous and pulmonary involvement were not correlated, although restrictive lung disease was more frequent in patients with diffuse form, whereas a trend to higher prevalence of pulmonary hypertension was observed in patients with limited cutaneous involvement.
15. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, Du Bois RM: Fibrosing alveolitis in systemic sclerosis. Arthritis Rheum 1997, 40:1229-1236. Sixty-four patients with fibrosing alveolitis associated with systemic sclerosis were studied using thin-section CT and static and exercise lung function testing. The percent predicted Dlco correlated better with extent of disease on CT than did oxygen desaturation on exercise or other measurements of pulmonary function.
16. Wells AU, Rubens MB, du Bois RM, Hansell DM: Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. Eur Respir J 1997, 10:280-285.
17. Matucci-Cerinic M: Sensory neuropeptides and rheumatic diseases. Rheum Dis Clin North Am 1993, 19;975-991.